Drug Landscape ›
Vitamin D3 ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 114,754
Most-reported reactions
Fatigue — 18,634 reports (16.24%) Diarrhoea — 12,734 reports (11.1%) Nausea — 12,722 reports (11.09%) Headache — 11,740 reports (10.23%) Drug Ineffective — 11,116 reports (9.69%) Pain — 10,737 reports (9.36%) Off Label Use — 10,331 reports (9%) Dizziness — 9,078 reports (7.91%) Dyspnoea — 8,911 reports (7.77%) Arthralgia — 8,751 reports (7.63%)
Source database →
Vitamin D3 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Vitamin D3 approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Vitamin D3 in United States?
Prisma Health-Midlands is the originator. The local marketing authorisation holder may differ — check the official source linked above.